Novavax skyrockets 23% after saying its COVID-19 vaccine showed promising results in an early trial (NVAX)

· *On Tuesday, Novavax announced that its COVID-19 vaccine "elicited robust antibody responses" in an early stage clinical trial.*
· *Shares of Novavax surged 23% in premarket trading Wednesday. *
· *The trial included 131 healthy adults between the ages of 18 and 59. It was conducted across two sites in Australia. *
·...